1. Home
  2. VIGL vs BRID Comparison

VIGL vs BRID Comparison

Compare VIGL & BRID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • BRID
  • Stock Information
  • Founded
  • VIGL 2020
  • BRID 1932
  • Country
  • VIGL United States
  • BRID United States
  • Employees
  • VIGL N/A
  • BRID N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • BRID Specialty Foods
  • Sector
  • VIGL Health Care
  • BRID Consumer Staples
  • Exchange
  • VIGL Nasdaq
  • BRID Nasdaq
  • Market Cap
  • VIGL 89.3M
  • BRID 93.2M
  • IPO Year
  • VIGL 2022
  • BRID N/A
  • Fundamental
  • Price
  • VIGL $2.58
  • BRID $10.30
  • Analyst Decision
  • VIGL Strong Buy
  • BRID
  • Analyst Count
  • VIGL 5
  • BRID 0
  • Target Price
  • VIGL $21.00
  • BRID N/A
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • BRID 2.0K
  • Earning Date
  • VIGL 03-25-2025
  • BRID 03-07-2025
  • Dividend Yield
  • VIGL N/A
  • BRID N/A
  • EPS Growth
  • VIGL N/A
  • BRID N/A
  • EPS
  • VIGL N/A
  • BRID N/A
  • Revenue
  • VIGL N/A
  • BRID $223,645,000.00
  • Revenue This Year
  • VIGL N/A
  • BRID N/A
  • Revenue Next Year
  • VIGL N/A
  • BRID N/A
  • P/E Ratio
  • VIGL N/A
  • BRID N/A
  • Revenue Growth
  • VIGL N/A
  • BRID N/A
  • 52 Week Low
  • VIGL $1.49
  • BRID $7.77
  • 52 Week High
  • VIGL $6.06
  • BRID $14.69
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 66.89
  • BRID 49.73
  • Support Level
  • VIGL $2.53
  • BRID $10.27
  • Resistance Level
  • VIGL $2.88
  • BRID $10.51
  • Average True Range (ATR)
  • VIGL 0.30
  • BRID 0.15
  • MACD
  • VIGL 0.06
  • BRID -0.03
  • Stochastic Oscillator
  • VIGL 70.98
  • BRID 54.76

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are processing and distribution of frozen products, and processing and distribution of snack food products. It includes products such as biscuits, bread dough items, roll dough items, dry sausage products, and beef jerky. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. It derives a majority of its revenue from snack food products.

Share on Social Networks: